Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Alvotech - Ordinary Shares (NQ:ALVO)

4.760 -0.090 (-1.86%)
Streaming Delayed Price Updated: 10:45 AM EST, Feb 12, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Alvotech - Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
News headline image
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Alvotech and Encourages Investors with Losses to Contact the Firm
From The Schall Law Firm
Via Business Wire
News headline image
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Alvotech (ALVO) on Behalf of Investors
From Glancy Prongay & Murray LLP
Via Business Wire
News headline image
The Law Offices of Frank R. Cruz Announces Investigation of Alvotech (ALVO) on Behalf of Investors
From The Law Offices of Frank R. Cruz
Via Business Wire
News headline image
Earnings Scheduled For March 1, 2023 ↗
Companies Reporting Before The Bell • Globalstar (AMEX:GSAT) is expected to report quarterly loss at $0.01 per share on revenue of $38.75 million. 
Via Benzinga
News headline image
Why Shares of Alvotech Jumped This Week ↗
The Icelandic biotech company has a deal to expand the reach of its Humira biosimilar in Eastern Europe. 
Via The Motley Fool
News headline image
Why Teva Pharmaceutical Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗
Gainers SAI.TECH Global Corporation (NASDAQ: SAI) jumped 269% to $5.61 after gaining around 25% on Thursday. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Alvotech Provides Regulatory Update on AVT02 Biologics License Application
From Alvotech
Via GlobeNewswire
News headline image
Alvotech Provides Update on Corporate Sustainability Framework
From Alvotech
Via GlobeNewswire
News headline image
Alvotech to Present Clinical Study Data for AVT04, a Proposed Biosimilar to Stelara®, at 2023 American Academy of Dermatology (AAD) Annual Meeting
From Alvotech
Via GlobeNewswire
News headline image
Alvotech Reports Financial Results for Full Year 2022 and Provides Business Update
From Alvotech
Via GlobeNewswire
News headline image
uniQure Stock Trying To Close In On Key Technical Measure ↗
uniQure stock had its Relative Strength Rating upgraded to 79 Tuesday -- a nice improvement, but still shy of the 80-plus desired score. 
Via Investor's Business Daily
News headline image
Alvotech Announces Webcast of 2022 Full Year Financial Results at 8:00 am ET on March 2, 2023
From Alvotech
Via GlobeNewswire
News headline image
Settlement of Alvotech Private Share Placement Completed
From Alvotech
Via GlobeNewswire
News headline image
EMA Confirms Acceptance of Application for AVT04, a Proposed Biosimilar to Stelara® (ustekinumab)
From Alvotech
Via GlobeNewswire
News headline image
Alvotech Enters Into Commercialization Agreement With Advanz Pharma for Proposed Biosimilar to Xolair® (Omalizumab)
From Alvotech
Via GlobeNewswire
News headline image
Alvotech and Bioventure Announce Approval of AVT02 (adalimumab) as Simlandi in Saudi Arabia
From Alvotech
Via GlobeNewswire
News headline image
Alvotech Completes $137 Million Private Share Placement
From Alvotech
Via GlobeNewswire
News headline image
Alvotech and Fuji Pharma Expand Partnership Adding a New Biosimilar Candidate
From Alvotech
Via GlobeNewswire
News headline image
Alvotech Initiates Pharmacokinetic Study for AVT05, a Proposed Biosimilar for Simponi® and Simponi Aria®
From Alvotech
Via GlobeNewswire
News headline image
Alvotech and Teva Announce Acceptance of U.S. Biologics License Application for AVT04, a Proposed Biosimilar to Stelara® (ustekinumab)
From Teva Pharmaceutical Industries Limited
Via Business Wire
News headline image
Alvotech and Teva Announce Acceptance of U.S. Biologics License Application for AVT04, a Proposed Biosimilar to Stelara® (ustekinumab)
From Alvotech
Via GlobeNewswire
News headline image
Why AMC Entertainment Shares Are Trading Lower By Around 13%? Here Are 59 Stocks Moving In Thursday's Mid-Day Session ↗
Gainers Core Scientific, Inc. (NASDAQ: CORZ) shares jumped 188% to $0.1471. Core Scientific shares dipped 75% on Wednesday after the company filed for Chapter 11 bankruptcy. 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
 
Via Benzinga
News headline image
MillerKnoll, Cleveland-Cliffs And Some Other Big Stocks Moving Higher On Thursday ↗
U.S. stocks traded lower, with the Dow Jones dropping over 400 points on Thursday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Update on U.S. Regulatory Status of AVT02, Alvotech’s Proposed High-Concentration, Interchangeable Biosimilar to Humira®
From Alvotech
Via GlobeNewswire
News headline image
Correction to Total Amount in Announcement About Private Placement Published 2022-12-16 09:00 GMT to headline field
From Alvotech
Via GlobeNewswire
News headline image
Alvotech Completes $59.7 Million Private Placement
From Alvotech
Via GlobeNewswire
News headline image
Alvotech Shares Start Trading on Nasdaq Iceland Main Market
From Alvotech
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.